Review: Peroxisome Proliferator-Activated Receptor-γ and Its Role in the Development and Treatment of Diabetes

por Leff, Todd, Mathews, Suresh T., Camp, Heidi S.
Publicado 2004

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

por Mohamed, Mohamed‐Eslam F., Klünder, Ben, Camp, Heidi S., Othman, Ahmed A.
Publicado 2019

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

por Mohamed, Mohamed‐Eslam F., Beck, Denise, Camp, Heidi S., Othman, Ahmed A.
Publicado 2019

Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis

por Ezzedine, Khaled, Soliman, Ahmed M., Li, Chao, Camp, Heidi S., Pandya, Amit G.
Publicado 2023

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects

por Mohamed, Mohamed‐Eslam F., Coppola, Sheryl, Feng, Tian, Camp, Heidi S., Kim, Elaine, Othman, Ahmed A.
Publicado 2021

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: resul...

por Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Publicado 2019

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumat...

por Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Publicado 2020

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

por Winthrop, Kevin L, Nash, Peter, Yamaoka, Kunihiro, Mysler, Eduardo, Khan, Nasser, Camp, Heidi S, Song, Yanna, Suboticki, Jessica L, Curtis, Jeffrey R
Publicado 2022

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

por Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Publicado 2016

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

por Strand, Vibeke, Tundia, Namita, Wells, Alvin, Buch, Maya H, Radominski, Sebastiao C, Camp, Heidi S, Friedman, Alan, Suboticki, Jessica L, Dunlap, Kendall, Goldschmidt, Debbie, Bergman, Martin
Publicado 2020

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

por Genovese, Mark C., Smolen, Josef S., Weinblatt, Michael E., Burmester, Gerd R., Meerwein, Sebastian, Camp, Heidi S., Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven
Publicado 2016

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

por Parmentier, Julie M., Voss, Jeff, Graff, Candace, Schwartz, Annette, Argiriadi, Maria, Friedman, Michael, Camp, Heidi S., Padley, Robert J., George, Jonathan S., Hyland, Deborah, Rosebraugh, Matthew, Wishart, Neil, Olson, Lisa, Long, Andrew J.
Publicado 2018